eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2026-05-19 19 2 71844 article Muhammad Nabil 1 Anis Nadia Zulkifli 1 Mohamad Azwan Zai 1 Faculty of Health Science, Universiti Teknologi MARA Cawangan Pulau Pinang Kampus Bertam, Pulau Pinang, Malaysia Madecassoside, a primary pentacyclic triterpenoid saponin derived from Centella asiatica, exhibits a complex and highly versatile pharmacological profile characterized by significant context-dependent signaling modulation. Historically recognized for its therapeutic versatility in wound healing and systemic anti-inflammatory responses, its emerging application in oncology reveals a profound dualism. In normal physiological environments, madecassoside is cytoprotective, acting through the transient activation of the Nrf2 antioxidant axis. Conversely, it acts as a potent pro-apoptotic stimulus in malignant contexts. In triple-negative breast cancer, it induces a reactive oxygen species (ROS) surge that drives mitochondria-dependent apoptosis, while in hepatocellular carcinoma, it functions as a targeted antagonist, effectively blocking the cMET receptor pathway. To reach these anticancer effects, the body needs a specific therapeutic window of 25–100µM. However, achieving this is a challenge because of the "Nrf2 Paradox"—where the same antioxidant pathway that protects healthy cells can accidentally act as a shield for established tumours. Beyond the main drug, madecassoside works within a powerful "Centella Network" alongside its structural sisters, asiaticoside and asiatic acid. Together, these compounds act as "chemosensitizers," helping standard drugs break through tumour resistance and reducing the harsh side effects of chemotherapy. Despite its potential and strong safety record, madecassoside faces a "Metabolic Gap". Upon oral administration, it undergoes rapid microbial degradation, leaving only 14.9% of the drug available to exert systemic effects. To bridge this gap, pharmaceutical engineering has developed "smart" nanogels. These pH-responsive carriers act as a protective barrier, keeping the drug stable until it reaches the acidic environment of a tumour, where it is precisely released. The final step in this roadmap is testing these nanostructures in Patient-Derived Xenograft (PDX) models. By using real human tumour structures instead of simple lab models, we can finally turn the promise of the Centella Network into a reality for precision oncology. https://biomedpharmajournal.org/vol19no2/the-madecassoside-switch-harnessing-centella-triterpenes-and-nanotechnology-for-precision-oncology/ Anticancer signaling Centellaasiatica Chemosensitization Madecassoside pH-responsive nanogels